Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses
Research and development	$ 1,421,851	$ 742,450	$ 3,360,563	$ 2,110,846
General and administrative	1,888,119	1,313,477	5,966,504	3,544,935
Total operating expenses	3,309,970	2,055,927	9,327,067	5,655,781
Operating loss	(3,309,970)	(2,055,927)	(9,327,067)	(5,655,781)
Change in fair value of common stock warrants		(128,300)		(280,747)
Warrant financing expense				(192,817)
Other income (expense)	104	(283)	242	(208)
Loss before income taxes	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Income taxes
Net loss	(3,309,866)	(2,184,510)	(9,326,825)	(6,129,553)
Deemed dividend attributable to preferred stock			(11,479,308)	(2,568,132)
Net loss applicable to common shareholders	$ (3,309,866)	$ (2,184,510)	$ (20,806,133)	$ (8,697,685)
Loss per common share -basic and diluted (in dollars per share)	$ (0.64)	$ (2.11)	$ (5.71)	$ (13.23)
Weighted average shares outstanding - basic and diluted (in shares)	5,183,492	1,034,262	3,645,682	657,184